Connext Successfully Completes Dose Escalation Part of CNT201 Phase 1/2 Clinical Trial for Dupuytren's Contracture
– Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease
SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Connext, a clinical stage biotechnology company, announced the successful completion of the dose escalation (Phase 1) part of its Phase 1/2 clinical trial for CNT201, its recombinant collagenase therapeutic for Dupuytren's contracture. The trial was conducted in an open-label format and confirmed both the safety and efficacy of CNT201: no dose-limiting toxicities were observed, and clear therapeutic benefits were demonstrated.
Key Clinical Results and Future Plans The study was conducted under a U.S. FDA-approved IND, using an open-label design to evaluate safety, tolerability, efficacy, pharmacokinetics, and immunogenicity.
The dose expansion (Phase 2) part is scheduled to begin in Q3 2025 as a double-blind study, aiming to demonstrate statistically significant efficacy.
Top-line data for the entire Phase 1/2 trial are expected in the first half of 2026, with plans to initiate global Phase 3 development in 2027.
The latest clinical development of CNT201 will be officially presented at the 'International Conference on Dupuytren Disease and Related Diseases' in Brussels in May 2025.
Differentiation Through Innovative Recombinant Collagenase
Currently, Endo's Xiaflex is the only commercially available collagenase injection for Dupuytren's contracture. CNT201 is being developed as an alternative to Xiaflex and is expected to significantly improve patient access to non-surgical treatment. Collagenase is originally produced by fermentation of the pathogenic microorganism Clostridium histolyticum, which carries inherent risks of contamination with various toxins. In contrast, CNT201 is the world's first recombinant collagenase therapeutic developed using genetic engineering technology, eliminating the risk of contamination from toxins or animal-derived substances. This ensures superior quality, consistent efficacy, and differentiated safety profiles.
Expanding Indications and Accelerating Global Drug Development
Connext is also pursuing a Phase 2 IND for Peyronie's disease, based on the same mechanism of action, and aims to obtain U.S. FDA IND clearance in 2025. Additional development for aesthetic indications such as cellulite is also underway.
Statement from Woo Jong Lee, CEO of Connext
'By confirming both safety and efficacy in the dose escalation part of Phase 1/2 study, CNT201 offers a new non-surgical treatment option for patients with Dupuytren's contracture. We aim to complete global new drug development with Phase 3 entry in 2027 and demonstrate the unique advantages of our innovative recombinant therapeutic,' said Woo Jong Lee, CEO of Connext.
Contact:
Sangho Lee, Head of Innovation
[email protected]
View original content: https://www.prnewswire.com/news-releases/connext-successfully-completes-dose-escalation-part-of-cnt201-phase-12-clinical-trial-for-dupuytrens-contracture-302445006.html
SOURCE Connext
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
2 minutes ago
- Bloomberg
BOJ Faces Costs From Deposit Facility as Market Eyes Rate Hike
As speculation mounts that the Bank of Japan will raise interest rates later this year, there's a growing risk that required payments to its deposit facility could put added strain on the bank's finances. Introduced 17 years ago by then-Governor Masaaki Shirakawa, the deposit facility pays interest on excess reserves deposited by financial institutions. The framework allows institutions to either park funds in excess of reserve requirements with the BOJ or lend them out in the market, thereby guiding short-term interest rates toward the facility's rate through arbitrage.
Yahoo
37 minutes ago
- Yahoo
Quantum Expands Distribution Network Across China, India, and the ASEAN Region to Accelerate Growth and Enhance Customer Experience in High-Growth, Data-Driven Markets
CENTENNIAL, Colo., August 05, 2025--(BUSINESS WIRE)--Quantum Corporation (Nasdaq: QMCO) today announced the strategic expansion of its distribution model across the high-growth technology markets of China, India, and the ASEAN region. Building on Quantum's strong foundation laid in the Asia-Pacific market, this expansion is designed to meet increasing demand for advanced data protection and management solutions, particularly as the growth of AI, machine learning, and unstructured data reshapes how organizations operate. To scale growth potential faster and more efficiently, Quantum has entered into exclusive distribution agreements with four regional leaders: ChangHong IT (CHIT) in China, Rashi Peripherals Limited in India, Hibino Graphics Corporation (formerly NGC) in Taiwan, and ACA Pacific in ASEAN. These partners bring technology expertise, deep local market knowledge, and long-standing relationships with Quantum, including established customer bases and technical alignment. "This move marks a pivotal chapter in Quantum's APAC strategy," said Rob Hilligoss, head of APAC sales for Quantum. "By aligning more deeply with trusted, long-term partners, we are accelerating our ability to deliver transformative data solutions at scale, across industries and borders. Our focus remains on customer experience, maintaining the highest service quality, and seizing the mounting growth opportunities in data-driven markets." The new channel model is designed to expand Quantum's market reach and enhance the customer experience with extended local service and support coverage, faster time-to-delivery, and tailored technical support. Each distributor will lead go-to-market efforts in their territory, invest in sales and marketing growth, and collaborate closely with Quantum to offer customers in the region support and services. This new channel model goes into effect immediately. For more information, visit About Quantum Quantum delivers end-to-end data management solutions designed for the AI era. With over four decades of experience, our data platform has allowed customers to extract the maximum value from their unique, unstructured data. From high-performance ingest that powers AI applications and demanding data-intensive workloads, to massive, durable data lakes to fuel AI models, Quantum delivers the most comprehensive and cost-efficient solutions. Leading organizations in life sciences, government, media and entertainment, research, and industrial technology trust Quantum with their most valuable asset – their data. Quantum is listed on Nasdaq (QMCO). Quantum and the Quantum logo are registered trademarks of Quantum Corporation and its affiliates in the United States and/or other countries. All other trademarks are the property of their respective owners. Forward-Looking Statements The information provided in this press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 ("Exchange Act"). These forward-looking statements are largely based on our current expectations and projections about future events and financial trends affecting our business. Such forward-looking statements include, in particular, statements about the anticipated benefits and features of Quantum's product distribution model, as well as our business prospects, changes and trends in our business and the markets in which we operate. These forward-looking statements may be identified by the use of terms and phrases such as "anticipates", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "plans", "projects", "targets", "will", and similar expressions or variations of these terms and similar phrases. Additionally, statements concerning future matters and other statements regarding matters that are not historical are forward-looking statements. Investors are cautioned that these forward-looking statements relate to future events or our future performance and are subject to business, economic, and other risks, and uncertainties, both known and unknown, that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, including without limitation, the following: risks related to the need to address the many challenges facing our business; the competitive pressures we face; risks associated with executing our strategy; the distribution of our products and the delivery of our services effectively; the development and transition of new products and services and the enhancement of existing products and services to meet customer needs and respond to emerging technological trends; whether the Asia-Pacific distribution model performs as anticipated and whether our products meet the developing needs of this market; and other risks that are described herein, including but not limited to the items discussed in "Risk Factors" in our filings with the Securities and Exchange Commission (the "SEC"), including our most recent Annual Report on Form 10-K filed with the SEC and any subsequent filings with the SEC. We do not intend to update or alter our forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law or regulation. View source version on Contacts Media Contact Matter Communications (Quantum)Sara Beth Faheyquantum@ 401.351.9507 Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45 th Annual Growth Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 45 th Annual Growth Conference on Wednesday, August 13, 2025 at 2:30 p.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X.
